Respiratory Medications in Infants <29 Weeks during the First Year Postdischarge: The Prematurity and Respiratory Outcomes Program (PROP) Consortium

29Citations
Citations of this article
52Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Objective: To determine patterns of respiratory medications used in neonatal intensive care unit graduates. Study design: The Prematurity Respiratory Outcomes Program enrolled 835 babies <29 weeks of gestation in the first week. Of 751 survivors, 738 (98%) completed at least 1, and 85% completed all 4, postdischarge medication usage in-person/telephone parental questionnaires requested at 3, 6, 9, and 12 months of corrected age. Respiratory drug usage over the first year of life after in neonatal intensive care unit discharge was analyzed. Results: During any given quarter, 66%-75% of the babies received no respiratory medication and 45% of the infants received no respiratory drug over the first year. The most common postdischarge medication was the inhaled bronchodilator albuterol; its use increased significantly from 13% to 31%. Diuretic usage decreased significantly from 11% to 2% over the first year. Systemic steroids (prednisone, most commonly) were used in approximately 5% of subjects in any one quarter. Inhaled steroids significantly increased over the first year from 9% to 14% at 12 months. Drug exposure changed significantly based on gestational age with 72% of babies born at 23-24 weeks receiving at least 1 respiratory medication but only 40% of babies born at 28 weeks. Overall, at some time in the first year, 55% of infants received at least 1 drug including an inhaled bronchodilator (45%), an inhaled steroid (22%), a systemic steroid (15%), or diuretic (12%). Conclusion: Many babies born at <29 weeks have no respiratory medication exposure postdischarge during the first year of life. Inhaled medications, including bronchodilators and steroids, increase over the first year.

References Powered by Scopus

Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network

2254Citations
N/AReaders
Get full text

Pediatric pulmonary hypertension

851Citations
N/AReaders
Get full text

Diminished Lung Function as a Predisposing Factor for Wheezing Respiratory Illness in Infants

597Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Lifelong pulmonary sequelae of bronchopulmonary dysplasia

46Citations
N/AReaders
Get full text

Outpatient Respiratory Management of Infants, Children, and Adolescents with Post-Prematurity Respiratory Disease An Official American Thoracic Society Clinical Practice Guideline

42Citations
N/AReaders
Get full text

Postnatal steroid management in preterm infants with evolving bronchopulmonary dysplasia

39Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ryan, R. M., Keller, R. L., Poindexter, B. B., D’Angio, C. T., Shaw, P. A., Bellamy, S. L., … Schmidt, B. (2019). Respiratory Medications in Infants <29 Weeks during the First Year Postdischarge: The Prematurity and Respiratory Outcomes Program (PROP) Consortium. Journal of Pediatrics, 208, 148-155.e3. https://doi.org/10.1016/j.jpeds.2018.12.009

Readers' Seniority

Tooltip

Professor / Associate Prof. 6

32%

PhD / Post grad / Masters / Doc 6

32%

Researcher 5

26%

Lecturer / Post doc 2

11%

Readers' Discipline

Tooltip

Medicine and Dentistry 16

62%

Nursing and Health Professions 5

19%

Biochemistry, Genetics and Molecular Bi... 3

12%

Social Sciences 2

8%

Save time finding and organizing research with Mendeley

Sign up for free